“We found that long-acting muscarinic antagonist (LAMA)-LABA therapy was associated with a lower risk of COPD exacerbations and a lower risk of pneumonia hospitalizations than inhaled ...

New users of LAMA-LABA therapy had a 20% reduction in the rate of first pneumonia hospitalization compared with new users of ICS-LABA (HR, 0.80; 95% CI, 0.75-0.86).

The other single-inhaler on the market for COPD ... colleagues' study provides assurance to patients and clinicians when choosing a dry-powder inhaler over a metered-dose inhaler of LABA-LAMA ...

• LAMA/LABA therapy now an essential cornerstone for COPD treatment across the spectrum of people with COPD in GOLD groups B-D 1 INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim ...

Lung function was significantly improved with LAMA/LABA therapy compared with patients receiving preoperative LAMA therapy (FEV1, 223.1 mL vs. 130 mL; FEV 1 percent predicted, 10.8% vs. 6.8%).

Source Reference: Vogelmeier C, et al "Stepping down from triple inhaled therapy to a LABA/LAMA fixed-dose combination: data from the German real-life DACCORD COPD cohort" ATS 2022.

Soon there will be "triple"-combination drugs consisting of a LABA, a LAMA, and an inhaled corticosteroid for COPD. The data surrounding their use are incomplete, however.

The most prescribed inhaler regimen was the guideline-concordant combination LAMA + LABA + ICS (15,574; 46.1%), followed by the guideline-discordant regimen ICS + LABA (7884; 23.3%) and short ...

The guideline provides evidence-based recommendations on the use of LABA/LAMA therapy, inhaled corticosteroids, and oral steroids in patients with COPD.

When RCT results were analyzed by eosinophil count, the reduction in exacerbations was greater with higher counts; therefore, they recommended LAMA/LABA therapy (without ICS) for group E COPD with ...

Numerous therapies are available, all of which can be divided into long- and short-acting β-agonists (LABA and SABA) and long- and short-acting muscarinic antagonists (LAMA and SAMA). 1 At a ...